Shanghai Kaibao Pharmaceutical CO.,Ltd: history, ownership, mission, how it works & makes money

Founded on April 12, 2000, Shanghai Kaibao Pharmaceutical Co., Ltd. has grown from a modern Chinese medicine startup into a publicly listed firm (SZ: 300039) known for products like Tanreqing injections and capsules (added in 2006), tiopronin for injection (2010), and Phlegm-Heat Clearing Capsules (Drug Registration Certificate obtained in 2015), expanded to Hong Kong in 2018, and reported milestones including CNY 1.2 billion revenue in 2020 (a 21.21% increase year-over-year) and, more recently, CNY 1.47 billion revenue in 2024 (down 7.57% from CNY 1.59 billion in 2023) with net income of CNY 375.55 million (up 14.55% year-over-year); the company is vertically integrated-covering R&D, manufacturing and distribution with about 1,225 employees as of December 31, 2024 (a 7.55% decline), invested CNY 350 million in R&D in 2023, has approximately 1.05 billion shares outstanding and a market capitalization of CNY 6.34 billion, reports a trailing EPS of CNY 0.33 and P/E of 18.34 with a dividend of CNY 0.10 (yield 1.66%), and features a governance structure dominated by major shareholder Kaiyi Trading (which signaled a planned reduction of up to 1% of its holdings between July 23, 2025 and October 22, 2025) alongside executives including General Manager Yingbin Zhou, Deputy GM Jianzhong Liu and Board Secretary Liwang Ren, positioning Kaibao at the intersection of traditional Chinese medicine and modern biopharma as it pursues domestic strength and international expansion

Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ): Intro

• Core therapeutic areas: heat‑clearing and detoxifying TCMs, respiratory anti‑infection products, liver‑function supportive injections.
• Key marketed products: Tanreqing capsules, Phlegm‑Heat Clearing Capsules, tiopronin for injection (liver function support).
• Market channels: hospital procurement, retail pharmacies, distributors, and export/HK subsidiary distribution.

• Listed entity: traded on Shenzhen Stock Exchange, ticker 300039.SZ.
• Shareholder composition: mixture of institutional investors, retail investors and company insiders (typical for Chinese listed pharma enterprises); strategic holders may include distributors or holding groups through block holdings.
• Subsidiaries: includes at least one Hong Kong subsidiary established in 2018 to support distribution and cross‑border business.

• Mission: develop and commercialize modern Chinese medicines that clear heat, detoxify, and support respiratory and liver health.
• R&D emphasis: product registration, clinical validation for TCM formulations and targeted chemical injections for liver therapy.
• Commercial strategy: expand product approvals, strengthen hospital and pharmacy channels, and grow regional distribution via subsidiaries.

• R&D & registration: internal R&D and regulatory submissions to obtain Drug Registration Certificates (e.g., Phlegm‑Heat Clearing Capsules in 2015).
• Manufacturing: GMP‑compliant production of capsule and injectable dosage forms for both TCM and chemical APIs.
• Distribution & sales: multi‑channel distribution-direct hospital supply, pharmacy chains, third‑party distributors, and Hong Kong arm for broader market access.
• Quality & compliance: ongoing regulatory liaison for product approvals and post‑market surveillance.

• 2020 revenue: CNY 1.20 billion.
• 2020 revenue growth vs. 2019: +21.21%.
• Revenue composition: weighted toward prescription/institutional sales and key branded TCM products (company disclosures emphasize product portfolio growth over these years).

Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ): History

Founded in the 1990s and listed on the Shenzhen Stock Exchange under ticker 300039, Shanghai Kaibao Pharmaceutical CO.,Ltd has evolved from a regional pharmaceutical manufacturer into a diversified specialty drug developer and distributor serving domestic and selected export markets. The company expanded through product line diversification, strategic partnerships, and investment in production capacity and R&D, culminating in a public listing that broadened its capital base and corporate governance profile.

• Listing: Shenzhen Stock Exchange, ticker 300039.SZ.
• Shares outstanding (as of 2024-12-31): ~1.05 billion shares.
• Market capitalization (as of 2024-12-31): CNY 6.34 billion.
• Core management: General Manager & Director Yingbin Zhou; Deputy General Manager & Non-Independent Director Jianzhong Liu; Board Secretary & Non-Independent Director Liwang Ren.

The ownership structure blends public float with concentrated private holdings led by major shareholders who exert material influence on strategic direction and corporate governance. Recent developments - notably Kaiyi Trading's announced up-to-1% disposal window in mid-2025 - may modestly alter voting dynamics and free-float levels.

• Public float drivers: retail and institutional investors accessing shares on Shenzhen exchange.
• Control influence: major shareholders (e.g., Kaiyi Trading) hold decisive sway on board composition and major corporate actions.
• Governance notes: board includes multiple non-independent directors linked to management/major stakeholders, reflecting the interplay of public and private interests.

For the company's stated purpose and guiding principles, see: Mission Statement, Vision, & Core Values (2026) of Shanghai Kaibao Pharmaceutical CO.,Ltd.

Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ): Ownership Structure

• Mission: develop innovative biopharmaceuticals-especially oncology and cardiovascular-by combining TCM knowledge with contemporary drug development techniques.
• Core values: patient-centered care, scientific innovation, sustainability, and community health education.
• 2023 R&D investment: CNY 350 million, reflecting a continued pivot toward pipeline enhancement and clinical development.

• 2023 reported R&D spend: CNY 350 million (company-declared).
• Pipeline focus: multiple oncology candidates in clinical or preclinical stages; cardiovascular biologics and TCM-derived small molecules progressing toward registration-enabling studies.
• Revenue & profitability (indicative recent-year scale): corporate disclosures typically show mid-to-high hundreds of millions CNY in revenue with reinvestment into R&D; net margins vary by product mix and clinical expense timing.

• Product sales: marketed pharmaceuticals combining TCM formulations and modern dosage forms for chronic cardiovascular and oncology-support indications.
• Licensing & partnerships: out-licensing of clinical-stage assets and co-development agreements with domestic and international partners.
• Contract research/manufacturing: leveraging internal capabilities for third-party projects to monetize capacity and expertise.
• Milestone & royalty streams: from strategic collaborations as pipeline assets reach regulatory and commercial milestones.

Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ): Mission and Values

Shanghai Kaibao Pharmaceutical Co., Ltd. operates through a vertically integrated model covering research, development, manufacturing and distribution of proprietary and generic pharmaceutical products. The company's strategic focus combines traditional Chinese medicine formulations with modern pharmaceutical technologies to serve respiratory, infectious and metabolic indications.

• Vertically integrated value chain: in-house R&D, clinical development, GMP manufacturing and national distribution.
• Core product portfolio: Tanreqing (injection and capsules), tiopronin (injection), Phlegm-Heat Clearing Capsules.
• Regulatory compliance: production facilities designed to meet domestic GMP and applicable international standards.

Key operational and organizational facts:

How it works - operational model and revenue drivers:

• R&D and product pipeline: internal teams focus on formulation optimization, clinical trials and post-marketing studies to sustain product lifecycle and support label extensions.
• Manufacturing: GMP-certified production lines produce both injectable and oral dosage forms; investments in automation and quality control aim to reduce batch deviation and improve yield.
• Sales and distribution: a nationwide sales force and distributor network market products across China; export and regional distribution are channeled through the Hong Kong subsidiary to facilitate international regulatory entry.
• Revenue composition: recurring sales from established branded products (notably Tanreqing) combined with income from newer formulations and potential hospital procurement contracts.

Product overview:

Operational metrics and strategic priorities:

• Headcount reduction of 7.55% to 1,225 employees (Dec 31, 2024) reflects cost and efficiency measures while maintaining core R&D and manufacturing capability.
• Ongoing capital allocation targets: facility upgrades, quality control automation, and clinical development support to maintain market share.
• Distribution expansion plan leverages the 2018 Hong Kong subsidiary to pursue regional registration and export opportunities.

For investor-focused details and ownership analysis see: Exploring Shanghai Kaibao Pharmaceutical CO.,Ltd Investor Profile: Who's Buying and Why?

Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ): How It Works

• Founded as a specialty pharmaceutical manufacturer focused on respiratory and infectious-disease therapies, Shanghai Kaibao has grown into a listed company on the Shenzhen Stock Exchange (code 300039.SZ).
• Core legacy products include Tanreqing formulations and tiopronin for injection, with continued R&D and production scale-up since listing.

• Publicly traded equity with a mix of institutional and retail investors; board and senior management drive product strategy, regulatory compliance, and commercialization.
• Significant shareholders typically include domestically focused asset managers and long-term strategic holders (ownership percentages vary with market transactions).

• Mission: develop, manufacture and commercialize effective therapies for respiratory and infectious conditions while maintaining regulatory quality and market access in China.
• Strategic priorities: protect flagship products, expand product mix (e.g., Phlegm-Heat Clearing Capsules), invest in manufacturing capacity, and navigate regulatory pathways.

• Primary revenue drivers: sales of marketed pharmaceuticals-Tanreqing injection and capsules, tiopronin for injection, and Phlegm-Heat Clearing Capsules.
• Revenue mix is product-driven; flagship products and volume-based hospital and retail channels generate the bulk of top-line sales.
• Pricing, tender wins, and reimbursement/insurance coverage determine realized margins and sales growth in hospital procurement markets.
• Supplemental income streams include minor contract manufacturing, licensing arrangements, and occasional one-time gains from asset adjustments or investment returns.

• Margins benefit from scale on core products and cost-control measures-evidenced by rising net income despite lower revenue in 2024.
• Revenue sensitivity factors: product demand shifts, intensified competition in generics and branded TCM-derived treatments, and regulatory approvals/changes affecting hospital procurement.
• R&D and manufacturing investments are required to sustain product lifecycle and defend pricing in tender-driven channels.

• Flagship products: Tanreqing injection and Tanreqing capsules (respiratory/infectious indications), tiopronin for injection (specialized therapeutic use), and Phlegm-Heat Clearing Capsules (traditional formula positioning).
• Primary channels: hospital tenders and procurement, pharmacy chains and retail outlets, and distribution partnerships for regional market penetration.

Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ): How It Makes Money

• Core revenue streams: prescription & OTC herbal formulations, proprietary modern TCM products, contract manufacturing and export sales.
• R&D & licensing: development of new formulations, out-licensing and co-development with domestic and overseas partners.
• Distribution & channels: hospital tenders, retail pharmacy chains, e-commerce, and expansion into MENA/ASEAN markets through HK subsidiary.
• Value drivers: product mix optimization, pipeline approvals, and cross-border registration to increase addressable markets.

• Financial health: solid profitability in 2024 with improving margins driven by higher-margin proprietary products and controlled manufacturing costs.
• Growth outlook: scaling exports via Hong Kong subsidiary, incremental revenue from new product launches and deeper penetration of hospital/retail channels.
• Risks: regulatory approvals, competition in both TCM and biopharma, and execution on international registrations.